Pentixapharm, a clinical-stage biopharmaceutical company, has announced a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a subsidiary of Eckert & Ziegler SE. Under the deal, EZR will produce patient-specific doses of Y90-PentixaTher, Pentixapharm’s CXCR4-targeting radiotherapeutic, for use in clinical trials.
Eckert & Ziegler SE, a provider of isotope technology, has announced a strategic partnership with Bicycle Therapeutics, a pharmaceutical company developing Bicycle Radio Conjugates (BRC molecules). Under the agreement, Eckert & Ziegler will supply various radioisotopes and provide development and manufacturing
Eckert & Ziegler has signed a global supply agreement with GlyTherix Ltd to provide Actinium-225 (Ac-225) in support of the latter’s clinical research and development of targeted radiotherapy. This collaboration extends the companies’ existing partnership, which is focused on Lutetium-177-based
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
